Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain
Withdrawn
Purdue Pharma LP
Phase 3
2011-11-01
The purpose of this study is to characterize the safety, pharmacokinetics (PK), and efficacy
of intravenous (IV) buprenorphine in pediatric patients.
Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
Completed
National Institute on Drug Abuse (NIDA)
Phase 3
2011-11-01
The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after
utero exposure to opioids. In an open label Phase 1 trial sublingual buprenorphine was
associated with a ~30% reduction length of treatment compared to standard of care morphine.
Due to the subjective nature of the scoring instrument, efficacy in a blinded trial is needed
to unequivocally establish the superiority of buprenorphine over morphine. The primary
objective of the trial is to compare length of treatment using sublingual buprenorphine or
oral morphine solution in the pharmacologic treatment of the NAS.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
